Q32 Bio Inc. announced positive 36-week topline results from Part B of the SIGNAL-AA Phase 2a clinical trial for bempikibart in patients with alopecia areata, showing a 35.3% mean reduction in SALT scores. The company also reported that it paid off the remaining $6.8 million balance of its loan with Silicon Valley Bank on June 24, 2026. Q32 Bio Inc. is a biotechnology company focused on developing therapeutic candidates for autoimmune diseases.
